Buy & Sell Canadian Natural Resources Ltd. (CNQ) – Canadian Natural Resources Ltd. Price Today
Aura AI Summary
Key Stats
- $95.61BMarket Cap
- EnergySector
- -14.94%3M Drawdown
- $107.08BEnterprise Value
- 4%Dividend Yield
- 62 daysTypical Hold Time
Canadian Natural Resources Ltd. (CNQ) is currently valued at a market capitalization of $95.61B, with an enterprise value of $107.08B. Over the past 52 weeks, Canadian Natural Resources Ltd. has traded between a low of $29.31 and a high of $50.55, highlighting its annual price range. Over the past three months, Canadian Natural Resources Ltd. has recorded a drawdown of -14.94%, reflecting recent price volatility. Canadian Natural Resources Ltd. offers a dividend yield of 4%, with the most recent dividend of $0.63 paid on 20 Mar 26. On average, investors hold Canadian Natural Resources Ltd. for approximately 62 days, indicating typical investor behavior on the platform.
About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Most Recent News
Digital Realty launches Malaysia data center operations to boost Southeast Asia's digital and AI infrastructure.
Digital Realty has officially launched its Malaysia operations with a new data center campus in Cyberjaya, aiming to expand its capacity to 32 MW. This development integrates Malaysia into Digital Realty's global network, supporting AI and data-drive...

Lockheed Martin and Boeing lag space stock rally; LMT upgraded to strong buy, BA to buy.
Lockheed Martin (LMT) and Boeing (BA) have not joined the recent surge in space-related stocks, largely due to ULA's lack of cost innovation and limited market fit compared to SpaceX. Their space segments contribute only a small portion of overall re...

Novartis to present key Phase III data on Rhapsido for chronic urticaria and food allergy at EAACI 2026.
Novartis will showcase results from multiple clinical trials of Rhapsido (remibrutinib) at the EAACI Congress 2026, including pivotal Phase III data for chronic inducible urticaria and extension data for chronic spontaneous urticaria. The presentatio...
